Improved immune responses and tuberculosis protection by aerosol vaccination with recombinant BCG expressing ESX-1 from Mycobacterium marinum - PubMed
5 hours ago
- #tuberculosis
- #vaccination
- #immune response
- The current BCG vaccine provides limited protection against pulmonary TB in adolescents and adults.
- A recombinant BCG strain, BCG::ESX-1Mmar, expressing ESX-1 functions from Mycobacterium marinum, enhances immune responses and TB protection.
- Aerosol vaccination with BCG::ESX-1Mmar or BCG Pasteur induces higher frequencies of CD4+ and CD8+ Th1 activated effectors and T effector memory cells in the lungs compared to subcutaneous vaccination.
- Aerosol vaccination elicits higher IL-17A responses, humoral IgG and IgA responses, and induces lung CD4+ and CD8+ T cells expressing tissue-residency markers.
- BCG::ESX-1Mmar provides superior T-cell immunity and protection against M. tuberculosis compared to parental BCG Pasteur for both vaccination routes.